Replies to post #2564 on Insmed Inc (INSM)

[readi29]

Omnitrope (somatropin [rDNA origin]), is a recombinant human growth hormone product indicated for long-term treatment of pediatric patients who have growth failure due to an inadequate secretion of endogenous growth hormone, and for long-term replacement therapy in adults with GHD of either childhood- or adult onset.

The normal cost of HGH is about 2000 a month, the articels that I have read indicate Omnitrope will reduce the cost another 25-45%. Therefore, if IPLEX were to attempt to get into the less serve market you look at a cost to the patient of about 1400 amonth.

[ToysInTheAttic]

Completely Concur Readi...

That market is already a who's-who in the pharm industry with products on the mkt or have ongoing trials for the less severe growth disorders. If it helps Butch..., grazing through clinictrails.gov is worth the time to see all the players in that field.

Correct me if i'm wrong please, but the trca trial is an extention of their previous trial so would it be germain to think that their going to use the 2X/day dosing for those patients,too? hmmm

tia and glta
added today, btw

s